Literature DB >> 8623915

Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties.

M Kämäräinen1, I Leivo, R Koistinen, M Julkunen, U Karvonen, E M Rutanen, M Seppälä.   

Abstract

Glycodelin is a glycoprotein with potent immunosuppressive and contraceptive activities. It reacts with antibodies against placental protein 14, or progesterone-associated endometrial protein, and has a unique carbohydrate structure. Previous nomenclature is misleading, because glycodelin is neither synthesized in the placenta nor is it endometrium specific. No ovarian synthesis of glycodelin has been demonstrated. We present evidence for glycodelin synthesis in the human ovary and ovarian tumors. In follicular phase, immunoperoxidase staining of microwave-treated tissue sections employing affinity-purified polyclonal antibodies localized glycodelin to areas of stromal cell condensation in ovarian cortex, theca interna, and the granulosa. In luteal phase, cortical stroma was negative or only weakly positive, whereas glycodelin was present in theca interna of the corpus luteum and luteinized granulosa cells and also in corpus albicans and Leydig cells of the ovarian hilus. In situ hybridization gave negative results for glycodelin mRNA in normal ovary, whereas in ovarian tumors strong expression of both the glycodelin mRNA and the protein were found in benign and malignant serous cystadenomas, mucinous ovarian tumors being negative. We conclude that glycodelin is synthesized in human ovarian tumors, and its occurrence in normal human ovary may represent either synthesis or a site of glycodelin action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623915      PMCID: PMC1861557     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Microwave stimulation of an immunological reaction (CEA/anti-CEA) and its use in immunohistochemistry.

Authors:  A Hjerpe; M E Boon; L P Kok
Journal:  Histochem J       Date:  1988 Jun-Jul

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Complete amino acid sequence of human placental protein 14: a progesterone-regulated uterine protein homologous to beta-lactoglobulins.

Authors:  M Julkunen; M Seppälä; O A Jänne
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Localization of luteinizing hormone, follicle-stimulating hormone, prolactin, and their receptors in human and rat testis using immunohistochemistry and radioreceptor assay.

Authors:  T Wahlström; I Huhtaniemi; O Hovatta; M Seppälä
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

5.  Time-resolved immunofluorometric assay for placental protein 14.

Authors:  L Riittinen; U H Stenman; H Alfthan; A M Suikkari; H Bohn; M Seppälä
Journal:  Clin Chim Acta       Date:  1989-08-15       Impact factor: 3.786

6.  Distribution of placental protein 14 in tissues and body fluids during pregnancy.

Authors:  M Julkunen; E M Rutanen; A Koskimies; T Ranta; H Bohn; M Seppälä
Journal:  Br J Obstet Gynaecol       Date:  1985-11

7.  Secretory endometrium synthesizes placental protein 14.

Authors:  M Julkunen; R Koistinen; J Sjöberg; E M Rutanen; T Wahlström; M Seppälä
Journal:  Endocrinology       Date:  1986-05       Impact factor: 4.736

8.  Serum levels of placental protein 14 reflect ovulation in nonconceptional menstrual cycles.

Authors:  M Julkunen; D Apter; M Seppälä; U H Stenman; H Bohn
Journal:  Fertil Steril       Date:  1986-01       Impact factor: 7.329

9.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

10.  Mapping of domains in human laminin using monoclonal antibodies: localization of the neurite-promoting site.

Authors:  E Engvall; G E Davis; K Dickerson; E Ruoslahti; S Varon; M Manthorpe
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  7 in total

1.  alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14.

Authors:  G J Riely; J Rachmilewitz; P H Koo; M L Tykocinski
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Immunolocalization of glycodelin in the genital tract of rats.

Authors:  Christiane Kunert-Keil; Esther Wiehmeier; Udo Jeschke; Jürgen Giebel
Journal:  J Mol Histol       Date:  2005-02       Impact factor: 2.611

3.  Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer.

Authors:  Udo Jeschke; Ioannis Mylonas; Christiane Kunert-Keil; Renate Stahn; Christoph Scholz; Wolfgang Janni; Christina Kuhn; Eike Schröder; Doris Mayr; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2008-10-14       Impact factor: 4.304

4.  Increased expression of glycodelin mRNA and protein in rat lungs during ovalbumin-induced allergic airway inflammation.

Authors:  Christiane Kunert-Keil; Udo Jeschke; Giles Simms; Michael Kasper
Journal:  Histochem Cell Biol       Date:  2008-11-12       Impact factor: 4.304

Review 5.  The Roles of Glycodelin in Cancer Development and Progression.

Authors:  Juan Cui; Yanguo Liu; Xiuwen Wang
Journal:  Front Immunol       Date:  2017-11-29       Impact factor: 7.561

6.  Higher follicular fluid glycodelin levels are negatively correlated with embryonic development in assisted reproduction.

Authors:  Sibel Bulgurcuoglu-Kuran; Bilge Ozsait-Selcuk; Funda Gungor-Ugurlucan; Gözde Koksal; Can Günay; Buyru Faruk
Journal:  JBRA Assist Reprod       Date:  2018-11-01

Review 7.  Recent Advances in Identifying Biomarkers and High-Affinity Aptamers for Gynecologic Cancers Diagnosis and Therapy.

Authors:  Xiaoqun Ma; Thangavel Lakshmipriya; Subash C B Gopinath
Journal:  J Anal Methods Chem       Date:  2019-09-08       Impact factor: 2.193

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.